MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press11410.17650/2782-3202-2024-4-2-55-64NEW DIRECTIONS AND ADVANCEMENTS IN TREATMENT OF ONCOLOGICAL DISEASES IN THE CURRENT AGEНОВЫЕ НАПРАВЛЕНИЯ И УСПЕХИ В ЛЕЧЕНИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ НА СОВРЕМЕННОМ ЭТАПЕPolatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical HospitalПолатузумаб ведотин в терапии диффузной В-клеточной крупноклеточной лимфомы: обзор литературы и опыт отделения онкогематологии Клинического госпиталя «Лапино»https://orcid.org/0000-0001-8443-8816RyabukhinaYu. E.РябухинаЮ. Е.
Russian Federation

Yulia E. Ryabukhina 

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Юлия Евгеньевна Рябухина 

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

gemonk.yur@mail.ruhttps://orcid.org/0000-0003-1564-424XZeynalovaP. A.ЗейналоваП. А.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081,

Bld. 2, 8 Trubetskaya St., Moscow 119991

Кафедра онкологии ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111,

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0002-6229-7300TimofeevaO. L.ТимофееваО. Л.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0002-2359-0547AbbasbeyliF. M.АббасбейлиМ. Ф.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0001-5353-8857ZhukovA. G.ЖуковА. Г.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0002-1469-2365ValievT. T.ВалиевТ. Т.
Russian Federation

Bld. 2, 8 Trubetskaya St., Moscow 119991

Кафедра онкологии

119991 Москва, ул. Трубецкая, 8, стр. 2

Clinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)140620244255641406202414062024Copyright ©; 2024, ABV-PressCopyright ©; 2024, АБВ-пресс2024ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/114

Study of molecular and genetic features of diffuse large B-cell lymphoma (DLBCL) suggests differential approach to treatment of this aggressive B-cell disorder characterized by short remission after each subsequent therapy line. Therefore, more effective regimens should be used at earlier stages. Identification of biological markers and their integration into prognostic scales can help to personalize therapy, especially in patients with high risk of quick progression and increase survival.

Our own experience of using immunoconjugate polatuzumab vedotin in therapy of patients with DLBCL. The use of Pola-BR combination in a patient with refractory non-GCB DLBCL allowed to achieve full remission alongside satisfactory tolerability and absence of significant adverse events. An evaluation of the Pola-R-CHP regimen in treatment of a patient with newly diagnosed generalized GCB DLBCL is presented.

Изучение молекулярно-генетических особенностей диффузной В-клеточной крупноклеточной лимфомы (ДВККЛ) предполагает применение дифференцированного подхода к лечению агрессивного В-клеточного заболевания, характеризующегосянепродолжительной ремиссией при каждой последующей линии терапии. В связи с этим целесообразно использование более эффективных режимов на ранних этапах заболевания. Выделение биологических маркеров и интеграция их в используемыепрогностические шкалы могут способствовать персонализированному подходу к терапии, особенно у пациентов с высоким риском быстрого прогрессирования, и увеличению выживаемости. Представлен собственный опыт применения иммуноконъюгата полатузумаба ведотина в терапии больных с ДВККЛ. Использование комбинации Pola-BR у пациента с non-GCB-вариантом рефрактерной ДВККЛ обеспечило достижение полной ремиссии наряду с удовлетворительной переносимостью и отсутствием значимых нежелательных явлений. Дана оценка применению режима Pola-R-CHP при лечении больного с впервые диагностированным GCB-вариантом генерализованной ДВККЛ

diffuse large B-cell lymphomapolatuzumab vedotinfull remissionmanageable safety profileдиффузная В-клеточная крупноклеточная лимфомаполатузумаб ведотинполная ремиссияуправляемый профиль безопасностиRuppert A.S., Dixon J.G., Salles G. et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020;135(23):2041–8. DOI: 10.1182/blood.2019002729Sehn L.H., Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021;384(9):842–58. DOI: 10.1056/NEJMra2027612WHO classification of tumours oh haematopoetic and lymphoid tissues. Ed. by S.H. Swerdlov, E. Campo, N.L. Harris et al. Revised 4th edn. WHO Press, 2017.Scott D.W., King R.L., Staiger A.M. et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 2018;131(18):2060–4. DOI: 10.1182/blood-2017-12-820605Rosenwald A., Bens S., Advani R. et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2019;37(35):3359–68. DOI: 10.1200/JCO.19.00743Hu S., Xu-Monette Z.Y., Tzankov A. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121(20):4021–31. DOI: 10.1182/blood-2012-10-460063Savage K.J., Slack G.W., Mottok A. et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016;127(18):2182–8. DOI: 10.1182/blood-2015-10-676700Devi K., Shaikh M.U., Ali N.B. et al. Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: a single-center experience. Leuk Res Rep 2021;16:100284. DOI: 10.1016/j.lrr.2021.100284Ma Q., Chang Y., Li L. et al. Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. Cancer Manag Res 2019;11:1363–72. DOI: 10.2147/CMAR.S192143Chen Y., Cai Q., Chang Yu. et al. High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma. Front Immunol 2022;13:1047115. DOI: 10.3389/fimmu.2022.1047115Nowakowski G.S., Chiappella A., Gascoyne R.D. et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021;39(12):1317–28. DOI: 10.1200/JCO.20.01366Davies A., Cummin T.E., Barrans S. et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 2019;20(5):649–62. DOI: 10.1016/S1470-2045(18)30935-5Younes A., Sehn L.H., Johnson P. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37(15):1285–95. DOI: 10.1200/JCO.18.02403Crump M., Neelapu S., Farooq U. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130(16):1800–8. DOI: 10.1182/blood-2017-03-769620Sawalha Y., Maddocks K. Profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: a brief report on the emerging clinical data. Onco Targets Ther 2020;13:5123–33. DOI: 10.2147/OTT.S219449Instructions for the medical use of the drug Polatuzumab vedotin, LP-006599.Инструкция по медицинскому применению препарата Полатузумаб ведотин, ЛП-006599.Polson A.G., Yu S.F., Elkins K. et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2017;110(2):616–23. DOI: 10.1182/blood-2007-01-066704Papageorgiou S.G., Thomopoulos T.P., Liaskas A., Vassilakopoulos T.P. Antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab. Cancers (Basel) 2022;14(8):1917. DOI: 10.3390/cancers14081917Assi R., Masri N., Dalle I.A. et al. Polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large B-cell lymphoma. Clin Hematol Int 2021;3(1):21–6. DOI: 10.2991/chi.k.210305.001Palanca-Wessels M.C., Czuczman M., Salles G. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015;16(6):704–15. DOI: 10.1016/S1470-2045(15)70128-2Morschhauser F., Flinn I.W., Advani R. et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 2019;6(5):e254–e65. DOI: 10.1016/S2352-3026(19)30026-2European Medicines Agency. POLIVY summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/polivy-epar-product-information_en.pdf (accessed 11.09.2020).Sehn L.H., Herrera A.F., Flowers C.R. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155–165. DOI: 10.1200/JCO.19.00172Sehn L., Hertzberg M., Opat S. et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 2022;6(2):533–43. DOI: 10.1182/bloodadvances.2021005794Tilly H., Morschhauser F., Sehn L.H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351–63. DOI: 10.1056/NEJMoa2115304Zhang W.R., Liu X., Zhong Q.Z. et al. Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer Med 2024;13(1):e6899. DOI: 10.1002/cam4.6899Herrera A.F., McCord R., Komes P. et al. Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): results from the POLARIX study. Blood 2022;140(Suppl 1):1297–300. DOI: 10.1182/blood-2022-157559Draft clinical recommendations “Aggressive non-follicular lymphomas - diffuse large-cell B-cell lymphoma, primary mediastinal B-cell lymphoma, Burkitt lymphoma”. Available at: https://rusoncohem.ru/klinrec/agressivnye-nefollikulyarnyelimfomy-proekt-2021-2022/ (acсess 15.12.2022).Проект клинических рекомендаций «Агрессивные нефолликулярные лимфомы – диффузная крупноклеточная В-клеточная лимфома, первичная медиастинальная В-клеточная лимфома, лимфома Беркитта». Доступно по: https://rusoncohem.ru/klinrec/agressivnye-nefollikulyarnye-limfomy-proekt-2021-2022/ (дата доступа: 15.12.2022).Sarkozy C., Sehn L.H. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol 2018;31(3):209–16. DOI: 10.1016/j.beha.2018.07.014Fabbri N., Mussetti A., Sureda A. Second-line treatment of diffuse large B-cell lymphoma: evolution of options. Semin Hematol 2023;60(5):305–12. DOI: 10.1053/j.seminhematol.2023.12.001Shi X., Liu X., Li X. et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and International Prognostic Index: a multicenter retrospective study. Front Oncol 2021;11:754964. DOI: 10.3389/fonc.2021.754964Pasqualucci L., Trifonov V., Fabbri G. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43(9):830–7. DOI: 10.1038/ng.892Hilton L.K., Scott D.W., Morin R.D. Biological heterogeneity in diffuse large B-cell lymphoma. Semin Hematol 2023;60(5):267–76. DOI: 10.1053/j.seminhematol.2023.11.006Schmitz R., Wright G.W., Huang D.W. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378(15):1396–407. DOI: 10.1056/NEJMoa1801445Chapuy B., Stewart C., Dunford A.J. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24(5):679–90. DOI: 10.1038/s41591-018-0016-8Abramson J.S., Solomon S.R., Arnason J.E. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood 2023;141(14):1675–84. DOI: 10.1182/blood.2022018730Locke F.L., Miklos D.B., Jacobson C.A. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640–54. DOI: 10.1056/NEJMoa2116133